106 results
8-K
EX-99.1
IMVT
Immunovant Inc
28 Nov 23
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
7:43am
in the conference call, please register in advance here. To access the live and archived webcast, please visit Immunovant’s website at https
S-3ASR
EX-1.2
IMVT
Immunovant Inc
9 Nov 23
Automatic shelf registration
8:49am
for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability … and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except in the case
424B5
cg427
29 Sep 23
Prospectus supplement for primary offering
4:48pm
8-K
EX-1.1
1iwnz8xailli6
28 Sep 23
Entry into a Material Definitive Agreement
5:23pm
8-K
EX-10.1
c1udf 02ns9x
28 Sep 23
Entry into a Material Definitive Agreement
5:23pm
424B5
6b0433jwmzh
26 Sep 23
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
x2qx9urdw9i6c8k7emq
26 Sep 23
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
7:45am
424B5
5fvj1i
5 Oct 22
Prospectus supplement for primary offering
4:43pm
8-K
EX-1.1
orjn5ku1pwk0rzde1k
4 Oct 22
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
5:28pm
8-K
EX-99.2
xb5zw8rsvrorimlfb
7 Sep 22
Regulation FD Disclosure
6:39am
8-K
EX-99.1
7athmobtzi5fyl
5 Aug 22
Results of Operations and Financial Condition
7:07am